hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients

Abstract

In this letter to the editor, the authors discuss the use of human equilibrative nucleoside transporter 1 (hENT-1) as a biomarker in patients with cholangiocarcinoma. They encourage standardization of techniques to evaluation expression of proteins such as hENT-1 and suggest additional studies investigating the active metabolites of gemcitabine, the use of liquid biopsies, and improved statistical methods.